Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast Cancer
Trial details
- Registry ID
- NCT07085767
- Phase
- Phase 3
Drug identity checked against registry records
Also recorded as OP-1250
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Palazestrant in Combination With Ribociclib for the First-line Treatment of ER+/HER2- Advanced Breast CancerNCT07085767 | — | Phase 3 | Recruiting | 2028-12Estimated |
| OP-1250 (Palazestrant) vs. Standard of Care for the Treatment of ER+/HER2- Advanced Breast CancerNCT06016738 | OLMA | Phase 3 | Active not recruiting | 2026-10-31Estimated |
| No regulatory events match this view.This does not mean no FDA events have occurred. |